205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (http://www.usitc.gov).

SUPPLEMENTARY INFORMATION:

Background

On January 7, 1999, the Commission determined that the domestic interested party response to its notice of institution (63 F.R. 52750, Oct. 1, 1998) of the subject five-year review was adequate. The Commission also determined that the respondent interested party response was inadequate because no respondent interested party responded to the Commission's notice. The Commission did not find any other circumstances that would warrant conducting a full review.[1] Accordingly, the Commission determined that it would conduct an expedited review pursuant to section 751(c)(3) of the Act.

Staff Report

A staff report containing information concerning the subject matter of the review will be placed in the nonpublic record on February 4, 1999, and made available to persons on the Administrative Protective Order service list for this review. A public version will be issued thereafter, pursuant to section 207.62(d)(4) of the Commission's rules.

Written submissions

As provided in section 207.62(d) of the Commission's rules, interested parties that are parties to the review and that have provided individually adequate responses to the notice of institution,[2] and any party other than an interested party to the review may file written comments with the Secretary on what determination the Commission should reach in the review. Comments are due on or before February 9, 1999, and may not contain new factual information. Any person that is neither a party to the five-year review nor an interested party may submit a brief written statement (which shall not contain any new factual information) pertinent to the review by February 9, 1999. If comments contain business proprietary information (BPI), they must conform with the requirements of sections 201.6, 207.3, and 207.7 of the Commission's rules. The Commission's rules do not authorize filing of submissions with the Secretary by facsimile or electronic means.

In accordance with sections 201.16(c) and 207.3 of the rules, each document filed by a party to the review must be served on all other parties to the review (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Determination

The Commission has determined to exercise its authority to extend the review period by up to 90 days pursuant to 19 U.S.C. § 1675(c)(5)(B).

Authority: This review is being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.62 of the Commission's rules.

Issued: January 13, 1999.

By order of the Commission.

Donna R. Koehnke,

Secretary.

[FR Doc. 99–1347 Filed 1–20–99; 8:45 am]

BILLING CODE 7020–02–P

[1] A record of the Commissioners' votes is available from the Office of the Secretary and at the Commission's web site.

[2] The Commission has found the response submitted by Chemical Products Corp. to be adequate. Comments from other interested parties will not be accepted (*see* 19 CFR 207.62(d)(2)).

INTERNATIONAL TRADE COMMISSION

[Inv. No. 337–TA–409]

Certain CD–ROM Controllers, and Products Containing Same-II; Notice of Commission Decision To Extend the Deadline for Determining Whether To Review an Initial Determination

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined to extend by seven (7) days, or until February 3, 1999, the deadline for determining whether to review an initial determination (ID)(Order No. 9) issued by the presiding administrative law judge (''ALJ'') in the above-captioned investigation.

FOR FURTHER INFORMATION CONTACT: John A. Wasleff, Esq., Office of the General Counsel, U.S. International Trade Commission, telephone 202–205–3094.

SUPPLEMENTAL INFORMATION: This investigation was instituted on May 7, 1998, based on a complaint filed by Oak Technology Inc (''Oak''). 63 Fed. Reg. 26625. Among the respondents is United Microelectronics Corp. (''UMC''). The complaint alleges, inter alia, that UMC engaged in unlawful activities in violation of section 337 through the unlicensed importation and sale for importation of goods infringing claims 1–5 and 8–10 of U.S. Letters Patent 5,581,715. Oak seeks the imposition of a cease and desist order and an exclusion order.

Complainant Oak filed a previous complaint before the Commission based on the same products and the same patent, naming UMC as a proposed respondent. Prior to institution of an investigation, Oak entered into a settlement/licensing agreement with UMC, and withdrew its complaint as to UMC. Prior to institution of the present investigation, UMC filed a letter with the Commission alleging that all its activities were authorized by the settlement agreement. Oak alleges that the sales and importation activities complained of are outside the provisions of the settlement agreement.

On August 28, 1998, the ALJ issued Order No. 7 terminating the investigation as to UMC for failure to state a section 337 claim. Complainant Oak and OUII filed petitions for review of the ID and UMC responded to those petitions. On October 7, 1998, the Commission reviewed and reversed Order No. 7.

In its opinion, the Commission noted that a motion for summary determination was pending, and stated that if the disposition of that motion came before the Commission, the Commission would ''address the matter as necessary and appropriate.'' On December 23, 1998, the ALJ issued Order No. 9 granting UMC's motion for summary determination. On December 31, 1998, complainant Oak filed a timely petition for review of the ID.

This action is taken under the authority of section 337 of the Tariff Act of 1930 (19 U.S.C. § 1337) and section 210.42(h)(3) of the Commission's Rules of Practice and Procedure (19 CFR § 210.42(h)(3).

Copies of the public version of the ID and all other nonconfidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street S.W., Washington, D.C. 20436, telephone 202–205–2000. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on 202–205–1810. General information concerning the Commission may also be obtained by accessing its Internet server (http://www.usitc.gov).

Issued: January 12, 1999.

By order of the Commission.

Donna R. Koehnke,

Secretary.

[FR Doc. 99–1348 Filed 1–20–99; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 332–402]

Advice Concerning the Addition of Certain Pharmaceutical Products and Chemical Intermediates to the Pharmaceutical Appendix to the HTS

AGENCY: United States International Trade Commission.

ACTION: Institution of investigation.

SUMMARY: Following receipt on December 23, 1998, of a request from the United States Trade Representative (USTR), the Commission instituted investigation No. 332–402, Advice Concerning the Addition of Certain Pharmaceutical Products and Chemical Intermediates to the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States, under section 332(g) of the Tariff Act of 1930 (19 U.S.C. 1332(g)).

At the request of USTR, the Commission will provide: (1) A summary description of the products contained in the existing Pharmaceutical Appendix and the modifications to be made to that Appendix; (2) an explanation of the relationship of the various elements in the Appendix to the HTS; and (3) estimates of current U.S. imports, and where possible, U.S. exports of the products included in the Pharmaceutical Appendix and the proposed additions to the Appendix, based on product groupings as necessary. The Commission will submit its report to the USTR no later than April 1, 1999.

EFFECTIVE DATE: January 13, 1999.

FOR FURTHER INFORMATION CONTACT: Information on general aspects of the study may be obtained from Elizabeth Howlett, Office of Industries (202–205–3365), or, on legal aspects of the investigation, contact William Gearhart of the Commission's Office of the General Counsel (202–205–3091).

Background

As one part of the Uruguay Round Agreements, the United States and 21 other countries agreed to the reciprocal elimination of duties, effective January 1, 1995, on approximately 7,000 pharmaceutical products and chemical intermediates used primarily for the production of pharmaceuticals. Commitments to eliminate duties on these products are reflected in each participant's market access schedule.

These countries also agreed to conduct a review, at least once every three years, to identify further products that could be covered by the pharmaceutical duty elimination initiative. The first review concluded with the addition of approximately 470 products, implemented on April 1, 1997. Participants, including the United States, are undertaking a second review, focusing on the addition of approximately 750 pharmaceutical products and chemical intermediates used primarily for the production of pharmaceuticals (a list of covered products is attached). According to USTR, these additional products represent products recommended by the U.S. private sector in response to a notice published by USTR in the **Federal Register** of December 29, 1997, as well as products proposed by the Governments of other participating countries. According to USTR, the Industry Sectoral Advisory Committee on Chemicals (ISAC–3) was consulted throughout the negotiations and this ISAC has endorsed the final list of products under consideration.

In section 111(b) of the URAA, Congress explicitly authorized the President to proclaim further modification of any duty for articles contained in a tariff category that was part of the U.S. ''zero-for-zero'' initiative. The Statement of Administrative Action which Congress approved in the URAA notes that the President would use section 111(b) authority to grant duty-free treatment for new pharmaceutical products such as those now under consideration. This authority is subject only to the conditions set forth in section 111 which include compliance with the consultation and layover provisions of section 115 of the URAA. One of the requirements set out in section 115 is that the President ''obtain advice regarding the proposed action'' from the Commission. Pursuant to section 115 and section 332(g) of the Tariff Act of 1930, USTR has requested that the Commission provide advice in the form of additional information on the pharmaceutical products and chemical intermediates currently under consideration.

Written Submissions

Interested persons are invited to submit written statements concerning the investigation. Written submissions should focus on the levels of exports and imports for the items included in this investigation. Written statements should be received by the close of business on February 17, 1999. Commercial or financial information which a submitter desires the Commission to treat as confidential must be submitted on separate sheets of paper, each clearly marked ''Confidential Business Information'' at the top. All submissions requesting confidential treatment must conform with the requirements of section 201.6 of the Commission's Rules of Practice and Procedure (19 CFR 201.6). All written submissions, except for confidential business information, will be made available for inspection by interested persons. All submissions should be addressed to the Secretary at the Commission's office in Washington, D.C. The Commission's rules do not authorize filing submissions with the Secretary by facsimile or electronic means.

Hearing-impaired individuals are advised that information on this matter can be obtained by contacting our TDD terminal on (202) 205–1810.

By order of the Commission.

Issued: January 14, 1999.

Donna R. Koehnke,

Secretary.

Additional Prefixes and Suffixes for Salts, Esters and Hydrates of INNS

Benzoate
Difumarate
Dipivoxil
Monobenzoate
Tetraisopropyl

INTERNATIONAL NONPROPRIETARY NAMES (INN) PROPOSED FOR DUTY ELIMINATION

INN	CAS RN
Abacavir	136470–78–5
Abafungin	129639–79–8
Abarelix	183552–38–7
Abiraterone	154229–19–3
Acreozast	123548–56–1
Agomelatine	138112–76–2
Alatrofloxacin	157182–32–6
Alinastine	154541–72–7
Almotriptan	154323–57–6
Almurtide	61136–12–7
Amelometasone	123013–22–9
Amlintide	122384–88–7
Apadoline	135003–30–4
Arcitumomab	154361–48–5
Aripiprazole	129722–12–9
Arofylline	136145–07–8
Aseripide	153242–02–5
Asimadoline	153205–46–0
Atiprimod	123018–47–3
Atizoram	135637–46–6
Atliprofen	108912–17–0
Atreleuton	154355–76–7